首页 | 本学科首页   官方微博 | 高级检索  
     


Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice
Authors:Jeff R. Crosby  Chenguang Zhao  Chong Jiang  Dong Bai  Melanie Katz  Sarah Greenlee  Hiroshi Kawabe  Michael McCaleb  Daniela Rotin  Shuling Guo  Brett P. Monia
Affiliation:1. Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA;2. The Hospital for Sick Children, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada;3. Max Planck Institute of Experimental Medicine, Göttingen, Germany
Abstract:

Background

Epithelial sodium channel (ENaC, Scnn1) hyperactivity in the lung leads to airway surface dehydration and mucus accumulation in cystic fibrosis (CF) patients and in mice with CF-like lung disease.

Methods

We identified several potent ENaC specific antisense oligonucleotides (ASOs) and tested them by inhalation in mouse models of CF-like lung disease.

Results

The inhaled ASOs distributed into lung airway epithelial cells and decreased ENaC expression by inducing RNase H1-dependent degradation of the targeted Scnn1a mRNA. Aerosol delivered ENaC ASO down-regulated mucus marker expression and ameliorated goblet cell metaplasia, inflammation, and airway hyper-responsiveness. Lack of systemic activity of ASOs delivered via the aerosol route ensures the safety of this approach.

Conclusions

Our results demonstrate that antisense inhibition of ENaC in airway epithelial cells could be an effective and safe approach for the prevention and reversal of lung symptoms in CF and potentially other inflammatory diseases of the lung.
Keywords:Cystic fibrosis  ENaC  Antisense oligonucleotide  Aerosol
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号